3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Lymphoma
58
Multiple Myeloma
52
Leukemia
48
Leukemia, Myeloid, Acute
44
Precursor Cell Lymphoblastic Leukemia-Lymphoma
41
Myelodysplastic Syndromes
37
Lymphoma, Non-Hodgkin
37
Hodgkin Disease
36
Lymphoma, Mantle-Cell
26
Lymphoma, Large B-Cell, Diffuse
26
Leukemia, Lymphocytic, Chronic, B-Cell
25
Lymphoma, Follicular
22
Breast Neoplasms
22
Burkitt Lymphoma
21
Lymphoma, B-Cell, Marginal Zone
16
Congenital Abnormalities
15
Lymphoma, Large-Cell, Immunoblastic
14
Recurrence
13
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
13
Sarcoma
12
Neoplasms, Plasma Cell
12
Hematologic Neoplasms
10
Leukemia, Myelomonocytic, Juvenile
9
Leukemia, Biphenotypic, Acute
9
Blast Crisis
9
Neoplasms
8
Myeloproliferative Disorders
8
Leukemia, Myelomonocytic, Chronic
8
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
7
Neuroblastoma
7
Interventions
Lenalidomide
3
Bortezomib
3
Dexamethasone
2
vandetanib
1
umbralisib
1
ublituximab
1
marizomib
1
durvalumab
1
carotuximab
1
avelumab
1
Zoledronic Acid
1
Vitamin D
1
Transplantation, Autologous
1
Tamoxifen
1
Standard of Care
1
Practice Guidelines as Topic
1
Palliative Care
1
Oxaliplatin
1
Melphalan
1
Leucovorin
1
Irinotecan
1
Granulocyte Colony-Stimulating Factor
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Filgrastim
1
Cyclophosphamide
1
Cisplatin
1
Carboplatin
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Disease Progression
×
Filgrastim
×
Clear all
NCT02043847
2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1
Completed
12 enrolled
12 charts